Novartis breast cancer drug Afinitor not cost effective for NHS, says draft NICE guidance
Swiss drug major Novartis’ (NOVN: VX) breast cancer drug Afinitor (everolimus) is not recommended as a National Health Service-funded treatment for a type of advanced breast cancer because it is not good value for money, says the latest draft guidance issued this morning (July 8) by the UK’s National Institute for Health and Care Excellence (NICE).
The NICE is currently assessing everolimus (in combination with the drug exemestane) as a treatment for HER2 negative, hormone-receptor-positive advanced breast cancer for a particular group of postmenopausal women. Despite not recommending the treatment, the draft guidance goes on to say that women who are already receiving everolimus should continue with the treatment until they and their doctor thinks it is appropriate to stop.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze